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INTRODUCTION N
Deepp vein thrombosis of the lower extremity is a frequently occurring disorder, with an estimatedd incidence of 2 per 1000 persons per year 1 . The primary objectives of treating patientss with venous thromboembolism (VTE) are to prevent death from pulmonary embolismm and to reduce the risk for recurrent thromboembolic events. For this purpose, patientt are treated with an initial course of heparin followed by a second phase of vitaminn K antagonists 24 . According to the ACCP consensus strategy a limited stratificationn in treatment duration is advocated, i.e., 3 months for patients with a transientt risk factor and one year or longer for patients with recurrent disease or a consistentt risk factor like thrombophilia or cancer 5 . This consensus is founded on the meann optimal duration of therapy obtained in large cohorts of patients and mainly basedd on the risk of recurrent venous thromboembolism, with only minimal considerationn for the patient's bleeding risk 6 " 8 . It is a well documented fact that the cumulativee risk of bleeding complications is determined by various risk factors. Major determinantss are the length of therapy and patients characteristics 910 . Therefore, the consensuss strategy has two major limitations. First, by not taking into account the bleedingg risk, a balanced decision on the duration of anticoagulant therapy can not be madee adequately. Second, decisions based on large cohorts neglect the fact that the riskk for bleeding and recurrent VTE are dependent on individual characteristics 1112 .
Thus,, rational decisions on the optimal duration of anticoagulant therapy for the individuall patient require knowledge of the risk of recurrence after discontinuation of treatmentt and the risk of bleeding during anticoagulant therapy. Ideally, treatment shouldd be continued until the benefits of treatment (i.e. prevention of recurrent VTE events)) are offset by the risks (i.e. major bleeding), considering that each patient has an individuall spectrum of risk factors for recurrent events and bleeding.
Sarasinn et al published their decision model in 1994 13 . They compared risk-benefit tradeoffss for treatment durations between 6 weeks and 6 months. Too obtain a solid baseline estimate for the incidence of recurrent VTE, studies were consideredd eligible when they included a cohort of patients in which all known thrombophilicc conditions were excluded. To obtain baseline estimates for major haemorrhagee during oral anticoagulant therapy, studies which made reference to the incidencee of major bleeding in the thromboembolic population were evaluated. For the identificationn of significant risk factors for recurrent VTE as well as bleeding during anticoagulantt therapy, articles that assessed the relative risk of such a risk factor were analysed.. Odds ratios for patients with a specific risk factor were calculated separately and,, when appropriate, pooled using the Mantel-Haenszel method 14 . To obtain estimatess on efficacy of vitamin K antagonist therapy, data were derived from studies, whichh reported on the incidence of recurrent VTE during vitamin K antagonist therapy.
Thee efficacy was expressed as relative risk reduction for a thromboembolic event, as comparedd to no treatment. Finally, the clinical course of DVT was assessed by evaluationn of clinical studies, which included long term follow-up.
Alll eligible studies were weighted for methodological strength, according to Sackettt et al 15 . In order to obtain high quality data, only those articles with the strongest methodologyy were selected for construction of the mathematical model.
Inn order to answer the question of how to balance the adverse events of antithromboticc management strategies, i.e. bleeding complications as a result of anticoagulantt therapy and recurrent VTE as manifestation of withholding anticoagulant therapy,, we sent out a questionnaire to 30 thrombosis-experts in the Netherlands.
Thee structure of the model is described in the section below. The parameters are summarizedd in Table I . 
RESULTS S

BaselineBaseline estimates for recurrent VTE
Too determine the baseline estimates for recurrent VTE in patients without oral anticoagulantt therapy two studies were identified in which all known thrombophilic conditionss were excluded in a subset of patients 1617 . Since the methodology of both studiess was comparable, both studies were combined to calculate the absolute recurrencee rate. As expected, the rate of recurrent events in this population declines exponentiallyy as a function of time. This decline is represented by the formula: Presence == 1.2xe t /i4+o.l
RiskRisk factors for recurrent VTE
Thee incidence of recurrent VTE in patients with the prothrombin G20210A mutation was reportedd in five studies 18 " 22 . The pooled odds ratio, using the Mantel-Haenzel method, is 1.44 (95% CI 0.9-2.0).
Eightt studies have been published which report on the incidence of recurrent venouss thromboembolism in patients with the Factor V Leiden mutation 8;16;18;19;2326 . In onee prospective study, the only decreased risk for recurrent VTE (odds ratio 0.5) was observed,, however data needed for the Mantel-Haenszel method could not be extracted fromm this study 8 . The calculated pooled odds ratio for the other 7 studies, using the Mantel-Haenszell method, is 1.3 (95% CI 1.0-1.7).
Severall studies reported on an increased risk of a first episode of venous thromboembolismm in patients with elevated plasma levels of factor VIII, however studies reportingg on the risk of recurrence are scarce. We have reported on a dose-dependent relativee risk for recurrent VTE, which was confirmed in another study 2728 . An odds ratio forr the risk of recurrence, using the Mantel-Haenszel method, was calculated for factor VIIII levels exceeding 200 lU/dl. This common odds ratio is 1.8 (95% CI 1.0-3.3).
Threee retrospective studies have assessed the risk for recurrent VTE in patients withh antithrombin, protein S or protein C deficiency 182930 . No prospective studies on the riskk of recurrence in untreated patients with antithrombin, protein C or S deficiency are available.. Data needed for the Mantel-Haenszel method could not be extracted. The estimatedd relative risk for a recurrent event based on these retrospective studies is 2.5.
Thee risk of recurrent VTE in patients with antiphospholipid antibodies has been studiedd in one retrospective 18 and three prospective studies 83132 . Since the original dataa did not provide sufficient information for the Mantel-Haenszel method, we estimatedd the overall risk to be 2.5.
Twoo studies have shown an increased risk for recurrent events in patients with highh levels of homocystein. In a prospective study, the relative risk was 2.6 33 . In a casecontroll study, an odds ratio of 3.1 was found 34 . By combining the results taking into accountt that case-control studies tend to overestimate the results, the relative risk was estimatedd to be 2.5.
Cancerr is generally considered to increase the risk of recurrent VTE. In two prospectivee cohort studies the relative risk for a recurrent event in cancer patients was Inn the absence of data from the literature, it is assumed that recurrent VTE without anyy underlying thrombophilic disorder is associated with a relative risk of 1.5.
Finally,, other potential risk factors (for example elevated levels of factor XI, renal insufficiency,, hypertension, smoking, obesity) were excluded from analysis, due to lack off data to estimate the risk of recurrent VTE.
MultiplyingMultiplying the baseline risk
Studiess comparing the risk for recurrent VTE in patients with a thrombofilic factor to the riskk in patients without a thrombophilic abnormality (our baseline population) show that thee exponential decline of VTE-events, as described above, is identical for patients with andd without a thrombophilic factor 163133 . This means that at any time elapsed since the event,, the difference in risk of recurrence between the two groups of patients is representedd by a constant factor, i.e. the relative risk for the specific thrombophilic condition.. Therefore the absolute risk of recurrent VTE at any specific time-point for the individuall patient with a certain thrombophilic abnormality is obtained by multiplying thee relative risk for this thrombophilic condition with the baseline risk for recurrent VTE att thiS time-point; Precurrence = (1-2 X e -'Z^+O.l) X RecurrenceWee assumed that the relative risk is constant at any time elapsed since the first event,, and that in the presence of two or more risk factors for recurrent VTE, the risk ratioss should be multiplied.
ClinicalClinical course of DVT and efficacy of treatment
Inn patients with DVT, approximately 20% of all recurrent events will be symptomatic PE 38 .. Thus, in order to achieve a curve representing the risk for developing PE following DVT,, the baseline curve should be multiplied with 0.2.
Too obtain the efficacy of treatment with vitamin K antagonists, a meta-analysis of fourr randomised trials was performed* 6 -8 , which showed an efficacy (i.e. a relative risk reductionn of the occurrence of VTE during oral anticoagulant treatment) of 93% (CI 86 to 977 %). We assumed that the efficacy of treatment remains stable at 90%. In conclusion, thee risk for the individual patient to develop a PE following DVT after stopping anticoagulantt treatment can be written as a function of baseline risk for DVT multiplied byy the relative risk obtained by a given risk factor and two constant factors (the risk for developingg PE after DVT (0.2) and the efficacy of treatment (0.9)); PrecurrencePE = 0.2 x 0.9 XX (1.2 X e -V" + 0.1) X RRrecurrence
BaselineBaseline estimates for major haemorrhage
Too determine the baseline estimate for major bleeding during anticoagulant therapy, we identifiedd one study in which in unselected patients using oral anticoagulants no selectionn was made and the long-term follow-up was performed. In this study 39 the patientss were categorised according to age, which was shown to be a major risk factor forr bleeding during oral anticoagulant therapy. The baseline estimate of haemorrhage wass therefore assessed by evaluating the risk of haemorrhage in the youngest category.
Forr this patient category, the baseline risk of major bleeding is consistent over time with ann incidence of 1 % per year (= 0.083%/month); Pbi eedmg = 0.083. As an assumption, we ignoredd the potentially higher risk of bleeding in the period when treatment with anticoagulantss is being initiated.
RiskRisk factors for major bleeding
Wee identified two risk factors for major haemorrhage: increasing age and the presence off cancer. In addition, other risk factors for major haemorrhage such as a history of gastrointestinall bleeding or cerebrovascular accident should be considered, but the quantitativee contribution of these factors to the bleeding risk is still unknown. In a study byy Van der Meer et al 39 , a relative risk of 1.5 for every 10 years increase in age above thee age of 40 years was observed for major bleeding. An odds ratio of 3.2 for an age abovee 65 was found in another cohort study 40 , which is comparable with the relative riskk in the study of Van der Meer et al for this age category. Two other articles with a lowerr methodological strength show identical results of elevated bleeding risks with increasingg age 4142 . Three cohort studies reported on the risk for major bleeding in patientss with malignant disease 124344 . The mean odds ratio for malignancy is approximatelyy 2.0. Whether there is a type of cancer specific odds ratio for bleeding cannott be inferred from the available literature. The individual risk for major haemorrhagee can be defined as a function of the baseline risk for developing a major bleedingg and the presence of a relative risk factor; Pbi eedi ng = RRbieeding x 0.083, and is assumedd to be constant over time, except for the fact that ageing is a risk factor which shouldd be corrected for. In the presence of two risk factors for major bleeding, the risk ratioss should be multiplied.
TheThe questionnaire
Thee results of the questionnaire among thrombosis-experts show that DVT is rated equallyy to minor bleeding, non-fatal pulmonary embolism as a manifestation of a recurrentt VTE is rated equally to major bleeding, and death due to PE is rated equally to deathh due to major bleeding (original data not shown). In our model, the risk for major bleedingg is outweighed against the risk for a PE as recurrent event. 
IntegrationIntegration of recurrence risk and bleeding risk
Orall anticoagulant treatment should ultimately be stopped at the time point at which thee benefit of treatment (i.e. prevention of recurrent VTE) is counterbalanced by its risk Withh use of the formula, the optimal time-point can be calculated for each individuall patient, since the relative risks for recurrent VTE and major bleeding are incorporated.. The exact position of the point of intersection of the two curves, and thereforee the optimal treatment duration, depends on the presence and quantity of the oddss ratios. When the patient is treated longer than his calculated optimal treatment duration,, the risk of PE is exceeded by the bleeding risk and the oral anticoagulant treatmentt could be harmful.
Too avoid complex calculations and potential calculation errors, we designed a simplee nomogram for daily clinical practice (Table II) , by which the optimal treatment durationn in months can be easily determined with use of the riskfactors for both recurrentt VTE and bleeding.
Too illustrate the clinical usefulness of the nomogram, three common clinical scenarioss are presented (Table III) Thee limitations, in general, of decision analyses are that they are based on data derivedd from literature. The baseline estimate for major bleeding is a critical element of thee model and it is supported by a single study. Indeed more studies are available which evaluatedd the risk of bleeding during anticoagulant therapy, but these studies included patientss with increasing age, whereas no adjustment for this considerable risk factor for bleedingg was performed. The incidence of recurrent thromboembolic events, one of the otherr key parameters in our model, is difficult to assess since only a limited number of studiess are available. However, a recently published meta-analysis confirmed that the riskk of recurrence decreases over time 47 . Some studies that evaluated the relative risk off recurrence in patients with a thrombophilic factor, especially carriers of the factor V Leidenn mutation, show conflicting results and are confined to relatively small number of patients.. However, we have included studies with a sound methodology only in our analysis. . Furthermore,, in this model we rated pulmonary embolism (as manifestation of a recurrence)) equal to major bleeding. Ideally, the patient's perception of the impact of thee non-fatal events and the quality of life associated with long-term anticoagulant therapyy should also be considered. In some patients, stopping treatment affects quality off life negatively because of a strong fear of a recurrent episode, whereas others experiencee anticoagulant treatment and its monitoring as a burden. This subjective estimationn of quality of life will probably have a great impact on the patient orientated optimall duration of treatment. Unfortunately, no reliable estimates of these variables
aree available yet.
Onee of the assumptions of the model is that in the presence of two or more risk factorss for recurrent VTE or major bleeding, these risk ratios should be multiplied. This is inn correspondence with Emmerich et al 48 , who described a complete multiplicative effectt of the combined Factor V Leiden and prothrombin mutation for the risk of a first episodee of VTE. Odds ratios were 4.9 and and 3.8 for the factor V Leiden and prothrombinn mutation, respectively. The odds ratio for VTE in double heterozygotes was 20.0.. Also for recurrent VTE a multiplicative effect of a double mutation was observed 18 .
Thiss multiplicative effect of risk factors is also described by several others 4950 . We are awaree of the fact that this assumption could induce an estimating simplification of realityy for some additive instead of multiplicative combinations of risk factors. However, duee to the fact that in our model, the number of risk factors for bleeding are outnumberedd by the risk factors for VTE, the optimal duration of VKA-therapy is more likelyy to be calculated too long than tot short, which is in line with the current ACCP consensuss strategy.
Recently,, two new factors for the prediction of a recurrent VTE are described. First, inn patients with persistent residual thrombosis confirmed by ultrasonography, recurrent diseasee is more frequent as compared to patients with early recanalization 51 . Second, Palaretii et al showed that the presence of increased D-dimer after discontinuation of orall anticoagulant therapy was associated with a higher risk for recurrent VTE 52 .
However,, more evidence is needed before these elements can be incorporated into the model. . Thee limitations of this kind of approach thus include the absence of hard data fromm management trials in which the proposed guidelines have been proven safe and effective,, the danger of propagating uncertainty, and the difficulty of assigning individuall patients to categories of risk. All these limitations are valid and attempts shouldd be undertaken in the future to reduce them.
Inn conclusion, since each patient has his own unique bleeding and thrombosis risk, decisionss about the duration of treatment should preferably be based on the individual riskk of recurrent thromboembolic events and the individual bleeding risk, rather than a predefinedd treatment duration which is uniform for a large subset of patients and is basedd primarily on the risk of recurrent VTE and doesn't take the patients bleeding risk intoo account. Application of an individual approach results in a balanced duration of treatmentt for each patient. Theoretically, this will lead to a lower incidence of recurrent DVTT and bleeding complications. To verify this statement, a prospective clinical study shouldd be initiated to validate the model.
